Zilebesiran, RNA interference (RNAi) therapeutic, and IONIS-AGT-LR, an antisense oligonucleotide (ASO), lower circulating angiotensin I, angiotensin II, and aldosterone, mitigating nocturnal blood pressure surges, fluid retention, and airway edema, all of which contribute to the pathophysiology of OSA-related hypertension. This evidence concerns the gene AGT and obstructive sleep apnea syndrome.